TY - JOUR
T1 - Health-related quality of life in curatively-treated patients with esophageal or gastric cancer: A systematic review and meta-analysis
AU - van den Boorn, H. ctor G.
AU - Stroes, Charlotte I.
AU - Zwinderman, Aeilko H.
AU - Eshuis, Wietse J.
AU - Hulshof, Maarten C. C. M.
AU - van Etten-Jamaludin, Faridi S.
AU - Sprangers, Mirjam A. G.
AU - van Laarhoven, Hanneke W. M.
N1 - Funding Information: This work was supported by The Dutch Cancer Society , grant number UVA 2014-7000 . Publisher Copyright: © 2020 The Author(s) Copyright: Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/10/1
Y1 - 2020/10/1
N2 - Surgery and chemoradiotherapy can potentially cure esophageal and gastric cancer patients, although they may impact health-related quality of life (HRQoL). We aim to systemically review and meta-analyze literature to determine the effect of curative treatments on HRQoL in esophageal and gastric cancer.— A systematic search was performed identifying studies assessing HRQoL. Meta-analyses were performed on baseline and subsequent time-points.— From the 6067 articles retrieved, 49 studies were included (61 % low quality). Meta-analyses showed short-term HRQoL differences between esophageal cancer patients receiving definitive chemoradiotherapy (dCRT), neoadjuvant chemo(radio)therapy (nC(R)T), or surgery alone (p < 0.001), with better HRQoL with nC(R)T and surgery compared to dCRT. Over the course of 12 months, no HRQoL difference was identified between treatments in esophageal cancer (p = 0.633). Esophagectomy, but not gastrectomy, resulted in a clinically relevant decline in HRQoL. No long-term HRQoL differences were identified between curative treatments in esophageal and gastric cancer. More high-quality HRQoL studies are warranted.
AB - Surgery and chemoradiotherapy can potentially cure esophageal and gastric cancer patients, although they may impact health-related quality of life (HRQoL). We aim to systemically review and meta-analyze literature to determine the effect of curative treatments on HRQoL in esophageal and gastric cancer.— A systematic search was performed identifying studies assessing HRQoL. Meta-analyses were performed on baseline and subsequent time-points.— From the 6067 articles retrieved, 49 studies were included (61 % low quality). Meta-analyses showed short-term HRQoL differences between esophageal cancer patients receiving definitive chemoradiotherapy (dCRT), neoadjuvant chemo(radio)therapy (nC(R)T), or surgery alone (p < 0.001), with better HRQoL with nC(R)T and surgery compared to dCRT. Over the course of 12 months, no HRQoL difference was identified between treatments in esophageal cancer (p = 0.633). Esophagectomy, but not gastrectomy, resulted in a clinically relevant decline in HRQoL. No long-term HRQoL differences were identified between curative treatments in esophageal and gastric cancer. More high-quality HRQoL studies are warranted.
KW - Curative treatment
KW - Esophageal cancer
KW - Gastric cancer
KW - Health-related quality of life
KW - Patient-reported outcome
KW - Quality-of-Life questionnaire
UR - http://www.scopus.com/inward/record.url?scp=85089410620&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.critrevonc.2020.103069
DO - https://doi.org/10.1016/j.critrevonc.2020.103069
M3 - Review article
C2 - 32818901
SN - 1040-8428
VL - 154
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
M1 - 103069
ER -